RT Journal Article
SR Electronic
T1 Vitamin D Supplements for Prevention of COVID-19 or other Acute Respiratory Infections: a Phase 3 Randomised Controlled Trial (CORONAVIT)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.22.22271707
DO 10.1101/2022.03.22.22271707
A1 David A. Jolliffe
A1 Hayley Holt
A1 Matthew Greenig
A1 Mohammad Talaei
A1 Natalia Perdek
A1 Paul Pfeffer
A1 Giulia Vivaldi
A1 Sheena Maltby
A1 Jane Symons
A1 Nicola L. Barlow
A1 Alexa Normandale
A1 Rajvinder Garcha
A1 Alex G. Richter
A1 Sian E. Faustini
A1 Christopher Orton
A1 David Ford
A1 Ronan A. Lyons
A1 Gwyneth A. Davies
A1 Frank Kee
A1 Christopher J. Griffiths
A1 John Norrie
A1 Aziz Sheikh
A1 Seif O. Shaheen
A1 Clare Relton
A1 Adrian R. Martineau
YR 2022
UL http://medrxiv.org/content/early/2022/06/24/2022.03.22.22271707.abstract
AB OBJECTIVES To determine whether population-level implementation of a test-and- treat approach to correction of sub-optimal vitamin D status (25-hydroxyvitamin D [25(OH)D] <75 nmol/L) influences risk of all-cause acute respiratory infection (ARI) or coronavirus disease 2019 (COVID-19).DESIGN Phase 3 open-label randomised controlled trial (CORONAVIT) utilising trials-within-cohorts (TwiCs) methodology.SETTING United Kingdom.PARTICIPANTS 6200 adults aged 16 years or older, who were not already taking vitamin D supplements at baseline.INTERVENTIONS Offer of a postal finger-prick test of blood 25(OH)D concentration with provision of a 6-month supply of higher-dose vitamin D (3200 IU/day, n=1550) or lower-dose vitamin D (800 IU/day, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, vs. no offer of testing or supplementation (n=3100). Follow-up was from 17th December 2020 to 16th June 2021.MAIN OUTCOME MEASURES The primary outcome was the proportion of participants experiencing at least one doctor- or swab test-confirmed ARI of any cause. Secondary outcomes included the proportion of participants developing swab test-confirmed COVID-19. Logistic regression was used to calculate odds ratios and associated 95% confidence intervals.RESULTS Of 3100 participants offered 25(OH)D testing, 2958 (95.4%) accepted, and 2690 (86.8%) had 25(OH)D <75 nmol/L and were sent vitamin D supplements (1356 higher-dose, 1334 lower-dose). 76 (5.0%) vs. 87 (5.7%) vs. 136 (4.6%) participants in higher-dose vs. lower-dose vs. no offer groups experienced at least one ARI of any cause (odds ratio [OR] for higher-dose vs. no offer 1.09, 95% CI 0.82-1.46; lower-dose vs. no offer 1.26, 0.96-1.66). 45 (3.0%) vs. 55 (3.6%) vs. 78 (2.6%) participants in higher-dose vs. lower-dose vs. no offer groups developed COVID-19 (OR for higher-dose vs. no offer 1.13, 0.78-1.63; lower-dose vs. no offer 1.39, 0.98-1.97).CONCLUSIONS Among adults with a high baseline prevalence of sub-optimal vitamin D status, implementation of a population-level test-and-treat approach to vitamin D replacement did not reduce risk of all-cause ARI or COVID-19.TRIAL REGISTRATION ClinicalTrials.gov no. NCT04579640What is already known on this topic?Vitamin D metabolites support innate immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory pathogens. Sub-optimal vitamin D status (25-hydroxyvitamin D <75 nmol/L) associates with increased susceptibility to all-cause acute respiratory infections (ARI) and coronavirus disease 2019 (COVID-19). Phase 3 randomised controlled trials of vitamin D to prevent COVID-19 have not yet reported.What this study adds This phase 3 randomised controlled trial, including 6200 participants, shows that implementation of a population-level test-and-treat approach to oral vitamin D replacement at a dose of 800 IU or 3200 IU per day did not reduce risk of all-cause ARI or COVID-19 among adults with a high baseline prevalence of sub-optimal vitamin D status.Competing Interest StatementJS declares receipt of payments from Reach plc for news stories written about recruitment to, and findings of, the COVIDENCE UK study. RAL declares membership of the Welsh Government COVID19 Technical Advisory Group. AS and JN declare research infrastructure report to the University of Edinburgh from ISCF/HDR UK. AS is a member of the Scottish Government Chief Medical Officers COVID-19 Advisory Group and its Standing Committee on Pandemics. He is also a member of the UK Governments NERVTAG Risk Stratification Subgroup. ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares support for attending meetings from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd and Abiogen Pharma Ltd. ARM also declares receipt of a consultancy fee from DSM Nutritional Products Ltd, and a speaker fee from the Linus Pauling Institute. ARM also declares participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195). ARM also declares unpaid work as a Programme Committee member for the Vitamin D Workshop. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd. All other authors declare that they have no competing interests.Clinical TrialNCT04579640Funding StatementThis study was supported by Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarchs Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Queens Square Research Ethics Committee, London, U.K. (ref 20/HRA/5095)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data will be provided on reasonable request to a.martineau@qmul.ac.uk subject to the terms of ethical approval and Sponsor requirements.